Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.

European journal of cancer (Oxford, England : 1990) - 1 Jun 2013

Lièvre A, Artru P, Guiu M, Laurent-Puig P, Merlin J L, Sabourin J C, Viguier J, Bastie A, Seronde A, Ducreux M

Abstract excerpt

BACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-epidermal growth factor receptor (EGFR) antibody in the treatment of metastatic colorectal carcinoma (mCRC). PATIENTS AND METHODS: This observational retrospective study was performed in 160 French centres during a 2-week period in 2011. Its main objective was to evaluate the rate of KRAS testing in patients with mCRC having initiated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to France

Share to Genes, ras

Share to Neoplasm Metastasis

Share to Practice Patterns, Physicians'

Share to Rectal Neoplasms

Share to Referral and Consultation

Source

Identifiers

PMID: 23473612
DOI: 10.1016/j.ejca.2013.02.016

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.PMID 23473612Read ↗

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.Semantic proximity Read ↗

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.Semantic proximity Read ↗

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].Semantic proximity Read ↗

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Semantic proximity Read ↗

[Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment].Semantic proximity Read ↗

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal CancerSemantic proximity Read ↗

Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.Semantic proximity Read ↗

Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries.Semantic proximity Read ↗

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS mutation testing in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations: analytical considerations.Semantic proximity Read ↗

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.